Paper42909080PubMed
Trifunctional antibody fusion proteins for targeted co-delivery of 4-1BBL with IL-15 or IL-21 to enhance antitumor immune responses.
Möller AM and 5 others. Front Immunol, 2026.
Cite this record
ConductScience Library. Trifunctional antibody fusion proteins for targeted co-delivery of 4-1BBL with IL-15 or IL-21 to enhance antitumor immune responses. Papers, record 42909080. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42909080
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Trifunctional antibody fusion proteins for targeted co-delivery of 4-1BBL with IL-15 or IL-21 to enhance antitumor immune responses.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't
- Revised in PubMed
- 2026-10-27
Source PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Interleukin-15 | Major topic |
| Recombinant Fusion Proteins | Major topic |
| Interleukins | Major topic |
| 4-1BB Ligand | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Interleukin-21 | |
| Cell Line, Tumor | |
| Animals | |
| Immunotherapy |
Source PubMed
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34064598 | CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34064598 | PubMed |
| 2 | 38739434 | IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/38739434 | PubMed |
| 3 | 27435400 | IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/27435400 | PubMed |
| 4 | 29511066 | 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. | J Exp Med | 2018 | https://conductscience.org/library/papers/29511066 | PubMed |
| 5 | 41283511 | CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB. | Antibodies (Basel) | 2025 | https://conductscience.org/library/papers/41283511 | PubMed |
| 6 | 23715927 | Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. | Cancer Immunol Immunother | 2013 | https://conductscience.org/library/papers/23715927 | PubMed |
| 7 | 41800025 | Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies. | Immune Netw | 2026 | https://conductscience.org/library/papers/41800025 | PubMed |
| 8 | 24198185 | Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy. | Mol Cancer Ther | 2014 | https://conductscience.org/library/papers/24198185 | PubMed |
| 9 | 31189721 | Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. | Sci Transl Med | 2019 | https://conductscience.org/library/papers/31189721 | PubMed |
| 10 | 19383914 | Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. | Cancer Res | 2009 | https://conductscience.org/library/papers/19383914 | PubMed |
| 11 | 12370353 | Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. | J Immunol | 2002 | https://conductscience.org/library/papers/12370353 | PubMed |
| 12 | 36699615 | Expanded NK cells used for adoptive cell therapy maintain diverse clonality and contain long-lived memory-like NK cell populations. | Mol Ther Oncolytics | 2023 | https://conductscience.org/library/papers/36699615 | PubMed |
| 13 | 18523273 | ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. | J Immunol | 2008 | https://conductscience.org/library/papers/18523273 | PubMed |
| 14 | 32357256 | Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. | Eur J Immunol | 2020 | https://conductscience.org/library/papers/32357256 | PubMed |
| 15 | 27831501 | Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. | Ann Oncol | 2017 | https://conductscience.org/library/papers/27831501 | PubMed |
| 16 | 39475618 | Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments. | Sci Adv | 2024 | https://conductscience.org/library/papers/39475618 | PubMed |
| 17 | 29866855 | Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29866855 | PubMed |
| 18 | 41081911 | CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/41081911 | PubMed |
| 19 | 39373147 | Targeted therapy of multiple myeloma by IL21-NKG2D CAR-T cells. | J Investig Med | 2025 | https://conductscience.org/library/papers/39373147 | PubMed |
| 20 | 36727218 | The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. | MAbs | 2023 | https://conductscience.org/library/papers/36727218 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42909080
GET https://conductscience.org/api/papers/v1/42909080/references?page=2